Katharina Robichon
Wellington, WGN, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Development and Application of an LC-MS Method for the Pharmacokinetics and Pharmacodynamics of Oral Therapeutic Efficacy of Nalfurafine.
Journal: Basic & clinical pharmacology & toxicology
Published: June 16, 2025
Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis.
Journal: Clinical & translational immunology
Published: June 04, 2025
Monitoring Treatment-Associated Receptor Expression in Multiple Sclerosis Using a Newly Developed Panel for Spectral Flow Cytometry.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology
Published: August 27, 2024
Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune-driven demyelination.
Journal: Clinical & translational immunology
Published: May 21, 2023
The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis.
Journal: Frontiers in neurology
Published: September 24, 2021
Functional genomics and metabolomics advance the ethnobotany of the Samoan traditional medicine "matalafi".
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 19, 2021
Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease.
Journal: Clinical & translational immunology
Published: October 02, 2020
Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis.
Journal: Journal of neuroinflammation
Published: November 28, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026